Business
Autonomix Medical, Inc. Granted New European Patent for First-in-Class Catheter-Based Technology
Global patent estate encompasses 80 issued patents and 40 pending patent applications Strengthens strategic position in a multi-billion-dollar market opportunity across cardiovascular, renal, and other high-burden diseases THE WOODLANDS, TX, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that European Patent Office (EPO) has granted Patent
About this update from Autonomix Medical, Inc.
[{"type":"image","alt":"Autonomix Medical, Inc.","displaySize":"","headline":null,"caption":"Autonomix Medical, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":174,"url":"https://media.zenfs.com/en/globenewswire.com/5cca67be9740fed2b1f7fe47e0e265b6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/yXZC_k658ygjAcliUe7Yow--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI0NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5cca67be9740fed2b1f7fe47e0e265b6","width":300,"height":174}},"lazy":false},{"type":"text","content":"Global patent estate encompasses 80 issued patents and 40 pending patent applications","length":85,"tagName":"p"},{"type":"text","content":"Strengthens strategic position in a multi-billion-dollar market opportunity across cardiovascular, renal, and other high-burden diseases","length":136,"tagName":"p"},{"type":"text","content":"THE WOODLANDS, TX, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that European Patent Office (EPO) has granted Patent No. 3,697,298 (the ‘298 patent), titled, “Medical Device with Circuitry for Capturing and Processing Physiological Signals.” The newly issued ‘298 patent relates to use of its proprietary technology to collect and process sensing data for real-time physiological monitoring with broad application use that includes coronary artery/vagal nerve mapping, arterial/renal mapping, bladder/lower urinary tract applications, robotic prosthetics and implants, and central nervous system monitoring for neurotherapy.","length":790,"tagName":"p"},{"type":"text","content":"“By protecting our proprietary circuitry for capturing and processing physiological signals in real time, we continue to strengthen the competitive moat around our technology which has broad, high-value applications across a number of indications. The ‘298 patent combined with 80 other issued patents positions us to capture opportunities across multiple multi-billion-dollar markets, create diverse revenue streams, and expand our global footprint as we advance toward potential commercialization in the future,” commented Brad Hauser, CEO of Autonomix.","length":555,"tagName":"p"},{"type":"text","content":"In particular, the ‘298 patent relates gene...